Program
KPC000154
A development code. Also written as “KPC000154 10mg Tablet Intervention”, “KPC000154 30mg Tablet Intervention” and “KPC000154 60mg Tablet Intervention”.
Its studies are led by Kunming Pharmaceuticals.
Furthest: phase 1, since Feb 27, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kunming Pharmaceuticals | 11 open or running | phase 1since Feb 27, 2025 | Feb 27, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2025First study: phase 1 study in Healthy Subjects、Lipid MetabolismFirst studyNCT06867406 · 92 planned · China
TargetBeta
THRB →read by rule
“KPC000154 is a thyroid hormone receptor beta (THR-β) agonist that improves NASH by increasing hepatic fat metabolism and reducing fat toxicity.”study text, by rule · the study
Other programs on THRB
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resmetiromrule | Madrigal Pharmaceuticals | phase 4 | 22 |
| KYLO-0603 | Sino Biopharmaceutical | phase 2 | 2 |
| CG-0416rule | hongkong-curegene-innovation-co-limited | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06867406Healthy Subjects、Lipid Metabolism · China | 1 | Not yet recruiting | Nov 30, 2025 | 92 |
How it is read
Names in the registry
- “KPC000154 10mg Tablet Intervention”, 1 entry
- “KPC000154 30mg Tablet Intervention”, 1 entry
- “KPC000154 60mg Tablet Intervention”, 1 entry
- “KPC000154 120mg Tablet Intervention”, 1 entry
- “KPC000154 200mg Tablet Intervention”, 1 entry
Codes read as this program: KPC000154.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.